A rapidly growing category of digital health interventions that combine software applications with clinical protocols to prevent, manage, or treat medical conditions, now eligible for reimbursement by public and private health insurance providers. IDTs cover a wide range of conditions including diabetes, hypertension, mental health disorders, and chronic pain, delivering evidence-based therapeutic interventions through mobile apps, wearables, and web platforms. The year 2026 marks a turning point for digital therapeutics, with the U.S. CMS and several European health systems establishing clear reimbursement pathways for FDA-cleared IDTs. Key requirements for insurance coverage include randomized controlled trial evidence demonstrating clinical efficacy, patient adherence tracking, and integration with electronic health records. By mid-2026, over 120 IDT products have been approved for insurance coverage globally, with average reimbursement rates of 75-90% of treatment costs. This shift has accelerated adoption by healthcare providers, with 62% of U.S. primary care practices now prescribing IDTs as part of standard treatment plans. Major pharmaceutical companies have also entered the space, acquiring digital therapeutic startups to complement traditional drug portfolios and improve patient outcomes through combined therapy approaches.